Democrats warn Trump about consequences of HIV prevention cuts
A group of more than 100 Democratic lawmakers sent a letter to President Donald Trump on Friday warning about the potential ...
2 FTSE 100 stocks that investors should consider for income
Our writer Ken Hall evaluates two defensive dividend payers in the FTSE 100 that he thinks investors should consider buying ...
GILD Stock Down on Report of Cut in HIV Prevention Spending
Gilead Sciences takes a hit after a Wall Street Journal reports state that the Trump administration is looking to slash ...
GSK Stock Recovers, Rises Around 17% YTD: Time to Buy, Sell or Hold?
We suggest that investors who own GSK's stock remain invested for now, considering its sales and profits are expected to continue improving in the coming years.
Fierce Healthcare2d
HHS may cut HIV prevention efforts at the CDC. Advocates fear changes will spike infections
The Department of Health and Human Services (HHS) is reportedly poised to slash funding for domestic HIV prevention at the ...
HIV Drug Makers Get Spooked by Possible Trump Cut, but Impact Looks Manageable
Gilead Sciences has been one of the best-performing large biotech companies over the past year, rising about 50%. That is largely due to excitement over its [long-acting HIV prevention drug]( ...
Why GSK plc (GSK) Is Among the Most Undervalued Biotech Stocks to Invest In
We recently published a list of the 7 Most Undervalued Biotech Stocks To Invest In. In this article, we are going to take a ...
Stock of the Day: Gilead Sciences falls on report the Trump administration could slash funds for HIV prevention
The Health and Human Services Department is considering cuts to HIV prevention funding, according to The Wall Street Journal.
Gilead Stock Falls on Report U.S. Could Slash HIV-Prevention Budget
The Health and Human Services Department is weighing plans to drastically cut funding for domestic HIV prevention, The Wall Street Journal reported. + The cuts could af ...
Gilead Stock (NYSE:GILD) Slumps on HIV Funding Cuts Report
Gilead Sciences (GILD) stock fell after The Wall Street Journal reported that the Health and Human Services Department is looking at ...
HIV Drugs Market Outlook: Future Trends Indicate a US$ 47.5 Billion Industry by 2034 with a Shift Toward Single-dose Regimens | Report by TMR
The HIV Drugs Market is expected to grow steadily from 2025 to 2035, driven by advancements in antiretroviral therapy and increasing global awareness initiatives. Rising HIV prevalence, improved ...